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Abstract
Background To compare immune responses following
neoadjuvant chemoradiation therapy in combination with
hyperthermia plus surgery to those induced by surgery
alone in patients with oesophageal cancer.
Methods Thirty-two patients with histopathologically
proven oesophageal cancer, scheduled for potentially cura-
tive transhiatal or transthoracic oesophagectomy with (neo,
n = 20) or without (control, n = 12) neoadjuvant thermo-
chemoradiation therapy (ThCR) were included. Peripheral
blood samples were obtained before ThCR, after 2 weeks
of ThCR, 1 day before surgery, on postoperative days 1, 3,
7, and 6 weeks after surgery, for white blood cell counts,
lymphocyte subsets and T helper type 1 (Th1) and type 2
(Th2) lymphocyte responses.
Results Neo patients showed a signiWcant decrease in
granulocytes and lymphocyte subsets, and T cell cytokines
after 2 weeks of ThCR. Only CD8+ (cytotoxic) T cells
recovered after ThCR to reach normal levels prior to sur-
gery. In contrast, CD4+ T (helper) cells, and NK- and B
cells in neo patients did not recover prior to surgery (all
P < 0.05). Oesophagectomy induced a signiWcant increase
in granulocytes and a decrease in lymphocytes (and sub-
sets). Only those subsets that had not recovered after ThCR
(CD4+ T cells, NK and B cells but not CD8+ T cells), were
signiWcantly lower (all P < 0.05) during the entire postoper-
ative study period. Postoperatively, the stimulated cytokine
production capacity of Th1 and Th2 cells, corrected for
number of T cells, was not signiWcantly diVerent between
the groups.
Conclusion Neoadjuvant thermochemoradiation for
oesophageal cancer caused signiWcant disturbances of host
cellular immunity with reduced T, NK and B cell counts,
and diVerential recovery of cytotoxic and helper T cells
leading to prolonged T cell imbalance that extends beyond
the time of surgery. The functional and anti-tumour conse-
quences of this immunodisturbance need further investiga-
tion, as recovery of T helper cytokine production towards
surgery was less impaired than T helper cell counts.
Keywords Oesophageal cancer · Neoadjuvant therapy · 
Surgery · Immune response · T cell imbalance
Introduction
Oesophageal cancer is associated with unfavourable prog-
nosis. Surgical resection is the best option when curation is
aimed for. However, even after surgery with curative intent,
overall survival is only 20–40% [9, 26]. Many institutes
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come, especially after the publication of favourable long-
term results of a randomised trial from the Medical
Research Council Oesophageal Cancer Working Party,
comparing neoadjuvant chemotherapy followed by surgery
versus surgery alone [23]. However, in a large proportion
of patients insuYcient objective response is achieved. To
improve these disappointing response rates, diVerent proto-
cols of preoperative chemoradiation therapy have been pro-
posed and evaluated [17]. Promising results have been
achieved with the addition of heat to chemotherapy or
radiotherapy. Hyperthermia is a treatment modality in
which oesophageal tissue is exposed to high temperatures
to damage and kill cancer cells, or to make cancer cells
more sensitive to the eVects of radiation and certain anti-
cancer drugs. In the Academic Medical Centre in Amster-
dam (the Netherlands), an external heating system has been
developed using the AMC 70 MHz four antenna array [8].
To evaluate the additional value of hyperthermia, a phase II
study was initiated, combining radiochemotherapy plus
deep regional hyperthermia (thermochemoradiation therapy =
ThCR) as neoadjuvant treatment in operable oesophageal
cancer patients.
Postoperative alterations in host immune functions after
major surgical interventions have been extensively
described and investigated [5, 6, 13]. A previous study by
our group, investigating the alterations in immune
responses after limited transhiatal oesophagectomy (THO)
and extended transthoracic oesophagectomy (TTO),
demonstrated that both THO and TTO severely suppressed
T helper type-1 (Th1) and type-2 (Th2) host immune
responses. The extent of the surgical procedure had a diVer-
ential immunosuppressive impact on Th2 cell activity (Th2
production of IL-4 and IL-13) but not on Th1 cell activity
(Th1 production of IL-2 and IFN-). The two operations
similarly impaired T helper type 1 cytokine production,
which indicates that the two T helper pathways were down
regulated through distinct mechanisms [42]. The addition
of preoperative thermochemoradiation therapy may sup-
press the immunological state of the patients even to a
greater extent than oesophagectomy alone, but only limited
data are available on immune responses after neoadjuvant
therapy followed by surgery [12, 20]. Furthermore, in the
interval between neoadjuvant therapy and surgery recovery
may take place, which is an important prerequisite for
immunocompetence during and after surgery. The host
recovery capacity and extent of recovery in the neoadjuvant
setting is not well known.
Therefore, the objective of this study was to compare
immunological parameters in patients with oesophageal
cancer subjected to curative surgery with and without
ThCR. Our analysis focused on the kinetics and recovery of
lymphocyte subsets as well as stimulated Th-cell cytokine
production that reXects the critical balance between Th1-
and Th2-mediated immune responses.
Methods
Patients
Between January 2004 and January 2005, 32 patients with
histologically proven cancer of the oesophagus or oeso-
phagogastric junction consented to participate in the pres-
ent study. All patients were scheduled for a potentially
curative oesophagectomy by either a limited transhiatal or
an extended transthoracic approach. Twenty patients under-
went neoadjuvant therapy prior to surgery (neo patients)
and 12 patients (control patients) underwent a potentially
curative oesophagectomy without preoperative therapy.
Patients younger than 75 years could participate in the pro-
spective nonrandomised trial to undergo neoadjuvant ther-
apy if there was less than 2 cm gastric involvement. Other
inclusion criteria were written informed consent and men-
tally, physically, and geographically able to undergo treat-
ment and follow-up. Exclusion criteria were diabetes;
uncontrolled heart failure, hypertension, severe arrhythmia,
and pacemaker; pre-existing myelopathy and/or polyneu-
ropathy; previous radiotherapy and/or chemotherapy;
age >75 years and <18 years.
Neoadjuvant therapy
Neoadjuvant therapy consisted of a 5-week schedule of
ThCR. The schedule was as follows: chemotherapy, con-
sisting of paclitaxel 50 mg/m2 and carboplatin AUC = 2, by
intravenous infusion on days 1, 8, 15, 22 and 29; radiother-
apy consisting of a total of 41.4 Gy, given in 23 fractions of
1.8 Gy, 5 fractions per week, starting day 1 of the Wrst cycle
of chemotherapy; and hyperthermia with concurrent che-
motherapy administration within 1 h after the radiotherapy
treatment. The hyperthermia method has previously been
described in detail by Albregts et al. [1]. Four to 6 weeks
after the end of neoadjuvant therapy, patients were sched-
uled for surgery.
Histopathological evaluation
All specimens were evaluated by an experienced gastroin-
testinal pathologist, in accordance with the criteria of the
International Union Against Cancer, including stage, R
classiWcation and grade. Tumours were classiWed as histop-
athologically responding when less than 10% viable tumour
tissue was found in the tumour bed; otherwise the tumour
was classiWed as histopathologically non-responding [44].
The group of non-responders was further divided into123
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tumour tissue), minimal response (>50% viable residual
tumour tissue), and no change (absence of any regressive
changes). In the group of responders, response was classi-
Wed as complete (histological Wbrosis with no viable resid-
ual tumour cells) and subtotal response (<10% viable
residual tumour cells) [21].
Blood sampling
Peripheral venous blood samples were obtained before neo-
adjuvant therapy, after 2 weeks of the start of neoadjuvant
therapy, 1 day before surgery, on postoperative days 1, 3, 7,
and 6 weeks after surgery (in total 7 sampling time points).
In control patients, blood was drawn at the same time
points except for the samples taken before and during neo-
adjuvant therapy (a total of 5 sampling time points).
Leucocytes and diVerential counts
The Beckman Coulter ACT DiV Analyser (Global Medical
Instrumentation, Inc., Ramsey, MN, USA) was used for
leucocyte and diVerential counts in peripheral venous blood
samples, collected in ethylenediamine tetra-acetic acid
(EDTA) tubes.
Flow cytometry
Peripheral venous blood samples were collected in EDTA
collection tubes. The monoclonal antibodies used for
immunophenotyping were from Becton Dickinson (San
Jose, CA, USA). Multitest reagents were used in combina-
tion with True Count Tubes and FACS Lysing Solution (all
Becton Dickinson), according to the instructions of the
manufacturer. The antibody combination CD3CD8CD45
CD4 or CD3CD16CD56CD45CD19 was applied: antibody
CD45 for lymphocytes, CD3 for T lymphocytes, CD3CD4
for T helper lymphocytes, CD3CD8 for T cytotoxic lym-
phocytes, CD3CD16CD56 for natural killer cells and CD19
for B lymphocytes.
Flow cytometric analysis was performed on an FACS
Calibur Xow cytometer (Becton Dickinson) using the Mul-
tiset software package (Becton Dickinson). A minimum of
2,000 and 5,000 lymphocytes were measured for T cell and
for NK and B cell analysis, respectively.
Whole blood cultures
Whole heparin blood was diluted 1:10 in Iscove’s modiWed
Dulbecco’s medium (IMDM; Boehringer Ingelheim, Alk-
maar, The Netherlands), supplemented with 0.1% faetal
calf serum, penicillin (100 IU/ml), streptomycin (100 g/ml),
and 15 IU/ml sodium heparin (Leo Pharmaceutical Prod-
ucts, Weesp, The Netherlands) and was cultured in tripli-
cate in Xat bottom 200-l wells (Nunc, Roskilde,
Denmark). In order to assay the stimulation of cytokines,
diluted whole blood was stimulated with anti-CD3 (CLB-
T3/4.E, 100 ng/ml) in concert with anti-CD28 (CLB-CD28/
1, 1 g/ml; Sanquin, Amsterdam, The Netherlands) for
cross-linking of T cell CD3 and CD28 receptors. Superna-
tants were harvested after 24 h (for IL-2) and after 72 h (for
IFN-, IL-4, and IL-13) and then stored at ¡80°C until
analyses.
Cytokine assays
Supernatant cytokine levels were measured using appropri-
ate combinations of singleplex assays from Bio-Rad
(Veenendaal, The Netherlands). Supernatant was diluted 1
in 4, using Bio-Plex human serum diluent, and Xuorescence
signals were analysed on the Bio-Plex reader after calibra-
tion with the high calibration setting. Cytokine production
per T cell was calculated by dividing the amount of each
cytokine (pg/ml) by the number of CD3+ cells.
Statistical analysis
All data were analysed using Statistical Software Package
version 12.0.2 (SPSS Inc., Chicago, IL, USA) for Windows
XP. Comparisons between groups were made using the
Mann–Whitney test (for continuous variables). To deter-
mine the eVect of neoadjuvant therapy on immune
responses, the Wilcoxon rank test was applied to compare
values 2 weeks after neoadjuvant therapy to those at base-
line. To determine the eVect of surgery on immune
responses, the Wilcoxon rank test was applied to compare
values of days after operation to those at baseline within the
group. Between-group diVerences over time were analysed
by a general linear model for repeated measures. By check-
ing, residuals were approximately normally distributed.
Standard descriptive analysis was performed for values at
baseline. In Wgures, data are presented as mean values §
one standard error of the mean. Statistical signiWcance was
deWned as P < 0.05 (two-sided).
Results
Clinicopathological data
Demographic characteristics, histopathological tumour indi-
ces and treatment-related complications were equally dis-
tributed among neo patients and control patients (Table 1).
Neo patients. The median patient age was 60 years (range
30–73 years) and most patients were male (90%). One
patient developed a mediastinitis due to neoadjuvant therapy.123
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the hospital), the following complications occurred (in 35%
of the patients): anastomotic leakage (n = 3) and pneumo-
nia (n = 3).
Control patients. The median age was 65 years (range
49–75 years), and most patients were male (75%). During
early postoperative period complications were observed in
25% of patients. One patient had anastomotic leakage; one
patient developed pneumonia, another patient suVered from
brain haemorrhage.
Histopathological response
Histopathological response evaluation revealed complete
response in 3 of the 20 neo patients (15%), subtotal
response in 6 patients (30%), partial response in 4 patients
(20%), minimal response in 6 patients (30%), and no
change in 1 patient (5%). There was no signiWcant diVer-
ence in immune response between responders and non-
responders to thermochemoradiation therapy.
Parameters of cellular immunity at baseline, during neoad-
juvant therapy, and prior to surgery
White blood cell and diVerential counts
Baseline values (values before ThCR for neo patients, and
values before operation for control patients) of white blood
cell (WBC) and diVerential cell counts were similar in neo
and control patients (Table 2).
After 2 weeks of ThCR, leucocytes, granulocytes
(Fig. 1), lymphocytes (Fig. 2), and monocytes decreased
signiWcantly in all neo patients as compared to pre-treat-
ment baseline values (P < 0.001, P = 0.001 and P = 0.007,
respectively). In the period between ThCR and operation,
there was a trend to recovery in leucocytes, granulocytes
and monocytes, although baseline values were not reached
(leucocytes: P = 0.004, monocytes: P = 0.255, data not
shown, granulocytes: P = 0.03, Fig. 1). Lymphocyte values
increased signiWcantly towards operation as compared to
the value after 2 weeks of ThCR (P = 0.002) but did not
reach baseline values (P < 0.001, Fig. 2).
Table 1 Clinicopathological parameters
Continuous variables are expressed as medians and ranges
Neo patients with preoperative treatment, control patients without pre-
operative treatment, tumour metastasis, SCC squamous cell carcinoma,
AC adenocarcinoma, TTO extended transthoracic oesophagectomy,
THO limited transhiatal oesophagectomy
* Mann–Whitney test (continuous variables) or Fisher exact test
(categorical variables)
Neo (N = 20) Control (N = 12) P value*
Age (years) 60 (30–73) 65 (49–75) NS
Gender (M:F) 18:2 9:3 NS
cTNM stage of 
disease (I/II:III/IV)
0/7:13/0 0/4:7/1 NS
SCC:AC 6:14 2:10 NS





Anastomotic leakage 3 1
Pneumonia 3 1
Brain haemorrhage 1
Table 2 Baseline values of leucocyte and lymphocyte subsets
Continuous variables are expressed as medians and ranges (x109/l);
before neoadjuvant therapy (neo) and before operation (control)
NK natural killer cells
* Mann–Whitney test (continuous variables)
Neo (N = 20) Control (N = 12) P value*
Leucocytes 6.7 (5.1–15.0) 7.7 (1.2–11.7) 0.851
DiVerential counts
Granulocytes 4.6 (2.7–12.3) 4.8 (0.5–6.9) 1.000
Monocytes 0.4 (0.01–1.8) 0.4 (0.2–2.1) 0.346
Lymphocytes CD45+ 1.8 (1.1–2.7) 2.2 (1.1–3.8) 0.350
Lymphocyte subsets
T lymphocytes (CD3+) 1.4 (0.7–2.0) 1.6 (0.7–2.4) 0.497
T helper (CD3+CD4+) 0.8 (0.2–1.1) 1.0 (0.6–1.8) 0.112
T cytotoxic (CD3+CD8+) 0.4 (0.2–1.1) 0.4 (0.1–0.7) 0.611
B cells (CD19+) 0.2 (0.05–0.4) 0.2 (0.05–0.6) 0.134
NK cells 
(CD3-CD16+CD56+)
0.2 (0.08–0.4) 0.3 (0.07–0.6) 0.276
Fig. 1 Granulocyte counts: patients with oesophageal cancer treated
with (dashed line with Wlled square, neo) and without (solid line with
Wlled triangle, controls) preoperative thermochemoradiation therapy.
Values after 2 weeks of neoadjuvant therapy versus baseline values:
P = 0.001. Preoperative values versus values after 2 weeks of neoadju-
vant therapy, P = 0.4; neo versus controls, 1 day preoperatively,
P = 0.07. Between-group diVerences over time in the 6 weeks postop-
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were signiWcantly lower in neo patients as compared to
control patients (P = 0.004 and P < 0.001, respectively).
This was in contrast to granulocytes (Fig. 1) and mono-
cytes which were not signiWcantly diVerent between
both groups at that time point (P = 0.07 and P = 0.28,
respectively).
Lymphocyte subsets
Baseline values of lymphocyte subsets were similar in neo
and control patients (Table 2).
After 2 weeks of ThCR, all lymphocyte subsets had
decreased signiWcantly (Figs. 3, 4, 5, 6). In the period
between ThCR and operation, neo patients showed a sig-
niWcant recovery in CD16+CD56+ NK cells (P = 0.001,
Fig. 5) and CD3+ T cells (P = 0.006, data not shown).
Remarkably, recovery of CD3+ T cells was only due to an
increase in CD8+ T cells and not in CD4+ T cells, since the
CD4+ cells remained low after the nadir due to ThCR
(Figs. 3, 4, 5). B cells did not recover after ThCR either
(Fig. 6).
Preoperatively, CD4+ T, NK and B cells were signiW-
cantly lower in the neo group as compared to the control
group (P < 0.001, P < 0.001, and P = 0.044, respec-
tively). In the neo group, the CD8+ T cells recovered
sharply in the preoperative period after ThCR and
showed to be the only lymphocyte subset that was at
similar level preoperatively as the control group
(P = 0.6).
Production of T lymphocyte-derived cytokines
Baseline values of Th1-type cytokines (IL-2 and IFN-)
and those of Th2-type cytokines (IL-4 and IL-13) in neo
and control patients were comparable (Table 3).
After 2 weeks of ThCR supernatant levels of both Th1-
type cytokines (IL-2 and IFN-) and Th2-type cytokines
(IL-4 and IL-13) were signiWcantly decreased (P = 0.003
and P = 0.011 and P = 0.003 and P = 0.013, respectively,
Fig. 2 Lymphocyte counts: patients with oesophageal cancer treated
with (dashed line with Wlled square, neo) and without (solid line with
Wlled triangle, controls) preoperative thermochemoradiation therapy.
Values after 2 weeks of neoadjuvant therapy versus baseline values:
P < 0.001. Preoperative values versus values after 2 weeks of neoadju-
vant therapy, P = 0.002; neo versus controls, 1 day preoperatively,
P < 0.001. Between-group diVerences over time in the 6 weeks postop-






























Fig. 3 CD3+CD4+ T cells counts (T helper cells) as determined by
Xow cytometry: patients with oesophageal cancer treated with (dashed
line with Wlled square, neo) and without (solid line with Wlled triangle,
controls) preoperative thermochemoradiation therapy. Values after
2 weeks of neoadjuvant therapy versus baseline values: P = 0.001. Pre-
operative values versus values after 2 weeks of neoadjuvant therapy,
P = 0.9; neo versus controls, 1 day preoperatively, P < 0.001. Be-




























Fig. 4 CD3+CD8+ T cells counts (T cytotoxic cells) as determined by
Xow cytometry: patients with oesophageal cancer treated with (dashed
line with Wlled square, neo) and without (solid line with Wlled triangle,
controls) preoperative thermochemoradiation therapy. Values after
2 weeks of neoadjuvant therapy versus baseline values: P = 0.001. Pre-
operative values versus values after 2 weeks of neoadjuvant therapy,
P = 0.007; neo versus controls, 1 day preoperatively, P = 0.6. Be-
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1842 Cancer Immunol Immunother (2008) 57:1837–1847shown for IL-2 and IL-4 in Fig. 7a and 8a). Cytokine
production per T lymphocyte (CD3+ cells) was not signiW-
cantly decreased (Table 4, Fig. 7b, 8b). For Th2-type
cytokine IL-13 even an increased production was found
(P = 0.001, Table 4) and also trendwise for IL-4
(P = 0.087, Fig. 8b).
Preoperative absolute values (absolute values and per T
lymphocyte) of both Th1-type cytokines and Th2-type
cytokines were somewhat lower in the neo group compared
to the control group, although not statistically signiWcant.
Postoperative parameters of cellular immunity
White blood cell and diVerential counts
Granulocyte counts increased signiWcantly after surgery in
both groups (P = 0.008 for neo and P = 0.005 for control at
postoperative day 1), and decreased to preoperative levels.
However, granulocytes were signiWcantly lower at 6 weeks
after surgery than at baseline in the neo patients (P = 0.04,
Fig. 1). The total leucocyte counts showed similar kinetics
as for granulocytes for each of the groups (data not shown).
Surgery had no clear eVect on monocytes in neo and
control patients (P = 0.88 for neo and P = 0.31 for control
patients, data not shown). In contrast, surgery induced a
profound reduction in lymphocyte counts in both groups
(P < 0.001 for neo and P = 0.003 for control patients, at
postoperative day 1, Fig. 2). Both groups recovered to pre-
operative levels 6 weeks after operation, although neo
patients did not reach baseline values (P = 0.003).
Between the two groups there was a signiWcant diVerence
over time postoperatively in leucocytes (P = 0.002), granulo-
cytes (P = 0.012, Fig. 1) and lymphocytes (P < 0.001,
Fig. 2), with the lower values for the neo patients.
Lymphocyte subsets
Postoperative CD3+ T cell numbers decreased signiWcantly
in both groups (P < 0.001 for neo patients and P = 0.003 for
control patients). Both groups recovered towards preopera-
tive levels 6 weeks after operation, although neo patients
did not reach baseline values (P = 0.004, data not shown).
Similarly, CD4+ and CD8+ T cells showed a decrease after
operation (P < 0.001 and P < 0.001, respectively, for neo
patients; P = 0.003 and P = 0.003, respectively, for control
patients; Figs. 3, 4). In the neo patients, the observed low
numbers of CD4+ T cells after neoadjuvant treatment
remained low during and after surgery, even after 6 weeks
(Fig. 3). In contrast, CD8+ T cells recovered relatively fast
Fig. 5 CD16+CD56+ NK cell counts as determined by Xow cytome-
try: Patients with oesophageal cancer treated with (dashed line with
Wlled square, neo) and without (solid line with Wlled triangle, controls)
preoperative thermochemoradiation therapy. Values after 2 weeks of
neoadjuvant therapy versus baseline values: P < 0.001. Preoperative
values versus values after 2 weeks of neoadjuvant therapy, P = 0.001;
neo versus controls, 1 day preoperatively, P = 0.044. Between-group
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Fig. 6 CD19+ B cell counts as determined by Xow cytometry: Pa-
tients with oesophageal cancer treated with (dashed line with Wlled
square, neo) and without (solid line with Wlled triangle, controls) pre-
operative thermochemoradiation therapy. Values after 2 weeks of neo-
adjuvant therapy versus baseline values: P < 0.001. Preoperative
values versus values after 2 weeks of neoadjuvant therapy, P = 0.1;
neo versus controls, 1 day preoperatively, P < 0.001. Between-group



























Table 3 Absolute baseline values Th1- and Th2 cytokines
Continuous variables are expressed as medians and ranges (pg/ml).
Before neoadjuvant therapy (neo) and before operation (control)
Neo patients with preoperative treatment, control patients without
preoperative treatment
* Mann–Whitney test (continuous variables)
Neo (N = 20) Control (N = 12) P value*
Th1
IL-2 3,388 (191–11,438) 2,909 (197–9,046) 0.525
IFN 2,288 (200–14,109) 1,423 (195–13,629) 0.445
Th2
IL-4 357 (63–2,498) 343 (79–4,233) 0.944
IL-13 358 (173–1,137) 400 (160–1,658) 0.866123
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vant therapy (Fig. 4). Hence, there were no diVerences in
preoperative and postoperative CD8+ T cell counts
between neo and control patients.
Similar to CD4+ T cell counts, also NK and B cell
counts that Wrst had decreased after neoadjuvant therapy
were persistently low levels during and after surgery. In
control patients, NK and B cell counts indeed decreased
after surgery but still remained signiWcantly higher than
counts in neo patients (P = 0.02 and P < 0.001, respec-
tively, Figs. 5, 6).
Production of T lymphocyte derived cytokines
Absolute levels of Th1-type cytokines (IL-2 and IFN-) and
Th2-type cytokines (IL-4 and IL-13) decreased signiW-
cantly 1 day after operation in the neo group (P < 0.001,
P = 0.002, P = 0.003 and P = 0.002, respectively). In the
neo group cytokine production per T lymphocyte showed a
Fig. 7 a Supernatant levels of T helper cell type 1 (Th1) cytokine IL-
2, expressed as absolute values in stimulated whole blood cultures
from blood samples: Patients with oesophageal cancer treated with
(dashed line with Wlled square, neo) and without (solid line with Wlled
triangle, controls) preoperative thermochemoradiation therapy. Values
after 2 weeks of neoadjuvant therapy versus baseline values:
P = 0.003. Preoperative values versus values after 2 weeks of neoadju-
vant therapy, P = 0.2; neo versus controls, 1 day preoperatively,
P = 0.08. Between-group diVerences over time in the 6 weeks postop-
erative period; P = 0.3. b Supernatant levels of Th1 cytokine IL-2 per
cell (corrected for no. of T cells): Patients with oesophageal cancer
treated with (dashed line with Wlled square, neo) and without (solid
line with Wlled triangle, controls) preoperative thermochemoradiation
therapy. Values after 2 weeks of neoadjuvant therapy versus baseline
values: P = 0.03. Preoperative values versus values after 2 weeks of
neoadjuvant therapy, P = 0.13; neo versus controls, 1 day preopera-
tively, P = 0.4. Between-group diVerences over time in the 6 weeks




































































Fig. 8 a Supernatant levels of T helper cell type 2 (Th2) cytokine IL-
4, expressed as absolute values in stimulated whole blood cultures
from blood samples: Patients with oesophageal cancer treated with
(dashed line with Wlled square, neo) and without (solid line with Wlled
triangle, controls) preoperative thermochemoradiation therapy. Values
after 2 weeks of neoadjuvant therapy versus baseline values:
P = 0.003. Preoperative values versus values after 2 weeks of neoadju-
vant therapy, P = 0.2; neo versus controls, 1 day preoperatively,
P = 0.1. Between-group diVerences over time in the 6 weeks postoper-
ative period; P = 0.4. b Supernatant levels of Th2 cytokine IL-4 per
cell (corrected for no. of T cells): Patients with oesophageal cancer
treated with (dashed line with Wlled square, neo) and without (solid
line with Wlled triangle, controls) preoperative thermochemoradiation
therapy. Values after 2 weeks of neoadjuvant therapy versus baseline
values: P = 0.009. Preoperative values versus values after 2 weeks of
neoadjuvant therapy, P = 0.09; neo versus controls, 1 day preopera-
tively, P = 0.2. Between-group diVerences over time in the 6 weeks


































































1844 Cancer Immunol Immunother (2008) 57:1837–1847comparable decrease in Th1- and Th2-type cytokine pro-
duction after operation, however only IL-2 decreased sig-
niWcantly (P = 0.008, see Fig. 7b). In the control group
there was a nonsigniWcant decrease in Th1- and Th2-type
cytokine production per T lymphocyte.
At day 3 after surgery a clear recovery in production of
IL-4 (absolute values and per T lymphocyte) was seen in
the control group, while the neo group remained low
(Fig. 8a, b). Six weeks after surgery graph lines of absolute
levels of cytokines of both groups had merged and were by
far similar. There was no signiWcant between-group diVer-
ence over time in both absolute and corrected levels of Th1-
and Th2-type cytokines (shown for IL-2 and IL-4 in
Figs. 7, 8).
Discussion
Major surgery is known to be associated with immune sup-
pression. Several studies, investigating alterations in
immune defence after oesophageal resection, have shown
that oesophagectomy depresses host immune response [41,
42]. However, little is known about the immunological
eVects of preoperative neoadjuvant treatment in these
patients [40].
The present study describes a broad spectrum of both
numerical and functional immunological parameters in a
series of surgical patients, some of whom received preoper-
ative treatment, while others were directly operated on. The
study population was uniform in that all patients had poten-
tially curable disease based on preoperative investigations,
and clinical parameters were comparable in both groups.
In brief, patients who received neoadjuvant thermo-
chemoradiation therapy demonstrated a signiWcant decrease
in the number of granulocytes and lymphocyte subsets. T
cell cytokine release was decreased after 2 weeks of neoad-
juvant therapy, while production per T helper cell remained
the same or showed a modest increase. CD8+ (cytotoxic) T
cells but not CD4+ (helper) T cells recovered in the period
between neoadjuvant therapy and operation. CD4+ T
(helper) cell cytokine production levels were almost recov-
ered, preoperatively.
All lymphocyte subsets that had not recovered after neo-
adjuvant therapy (i.e., CD4+ T cells, NK and B cells but
not CD8+ T cells) had persistent lower counts as compared
to control patients (operated without neoadjuvant therapy)
at 1 week postoperatively.
Hyperthermia causes a transient stimulation of the cell-
mediated immune response [38]. Recent research has
shown that, when cancer cells are heated to approximately
41.6°C, they form highly speciWc protein structures on their
surface known as heat-shock proteins [27]. These proteins
activate the patient’s own NK cells to attack the cancer
cells and stimulate the immune system [27]. Studies, evalu-
ating the immune response after chemotherapy and/or radi-
ation therapy, showed profound negative eVects on the
immune system [18, 22, 29, 36, 43]. In the present study,
the neo patients underwent a combination of chemotherapy,
radiotherapy and hyperthermia. The cumulative eVects of
this combination therapy led to a reduction of the white
blood cell count which resulted in an overall reduced
capacity to produce cytokines after 2 weeks of therapy.
Apparently, the immunosuppressive impact of chemoradia-
tion surpasses the immunostimulatory eVect of hyperther-
mia.
In patients with sepsis, the loss of lymphocytes, contrib-
uting to immunosuppression by decreasing the number of
available immune cells, is a well-known phenomenon.
However, relatively recent work implicates that, not only a
decrease in the number of eVector cells, but also lympho-
cyte apoptosis plays a potential factor in the immunosup-
pression in sepsis [16]. The apoptotic cells appear to have
important adverse eVects on immune function by actively
suppressing the inXammatory response [15]. It is unknown
at present whether lymphocyte apoptosis plays a role in
thermochemoradiation-induced immunosuppression, and
may be an important subject for further study.
The diVerential recovery of CD8+ cells in contrast to
CD4+ cells leading to a prolonged T cell imbalance after
thermochemoradiation therapy has been described by
Table 4 Values of Th1- and Th2-cytokines (corrected for number of T cells), in the 20 neo patients who received preoperative therapy
Neo, patients with preoperative treatment; continuous variables are expressed as medians and ranges (pg/CD3 cell); before neoadjuvant therapy
(baseline), 2 weeks of neoadjuvant therapy and preoperative
* Wilcoxon (continuous variables)
Baseline After 2 weeks P value* Preoperative P value* (vs. 2 weeks ThCR)
Th1
IL-2 2.94 (0.13–11.31) 3.59 (0.31–11.8) 0.255 1.58 (0.19–6.91) 0.125
IFN 1.79 (0.14–10.54) 1.15 (0.21–10.54) 0.605 0.52 (0.20–7.14) 0.053
Th2
IL-4 0.28 (0.04–1.76) 0.34 (0.08–2.62) 0.087 0.21 (0.04–2.01) 0.087
IL-13 0.30 (0.12–0.91) 0.76 (0.35–3.08) 0.001 0.60 (0.22–2.09) 0.109123
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blood stem cell transplantation [19, 31]. As most periphe-
ral CD4+ en CD8+ T cells share a common primary devel-
opmental pathway until relatively late in their
development, this signiWcant diVerence in the rate of
recovery is surprising. In short, T cell precursors move
from the bone marrow to the thymus, and develop to T
cells. In the thymus various T cell precursors can be distin-
guished by the expression of speciWc cell surface markers:
Wrst TCR (T cell receptor), second CD3 (which serves as
the signal transduction component of TCR), and Wnally
CD4/CD8. It could be hypothesised that the regeneration
of both CD4+ and CD8+ T cells occurs exclusively via
thymic dependent pathways [19]. However, there is no
existing evidence to suggest that a suboptimal thymic
regenerative capacity would preferentially aVect
CD4+ populations, which could explain the diVerential
recovery rate [3, 32, 37]. Alternatively, extrathymic gener-
ation of CD8+ cells from haematopoietic precursors could
be involved and/or peripheral expansion of mature
CD8+ T cells, which remain in the secondary lymphoid
tissues after completion of chemotherapy. Mackall et al.
[19] suggested that extrathymic lymphopoiesis is involved,
as in their study the predominance of CD8+ cells lacked
CD28 expression. This lack of CD28 expression has been
associated with impaired thymic function in HIV infection
[4], post-bone marrow transplantation [2, 24], and aged
hosts [34]. Expansions of CD8+CD57+ cells have also
been described in combination with restricted T cell reper-
toire diversity [11]. Thus, the relatively rapid regeneration
of CD8+ cells compared to the slow CD4+ regeneration
might be due to thymic independent pathways that
eYciently and selectively induce regeneration of distinct
CD8+ subsets.
Furthermore, diVerences in sensitivity of the factors that
regulate homoeostatic proliferation of memory CD8+ T
cells as compared to memory CD4+ T cells may explain the
slower recovery of the CD4+ T cell-population from ther-
mochemoradiation. Homoeostatic proliferation of CD8+ T
cells seems to depend on IL-15 and IL-7, whereas these
cytokines are probably not required for homoeostatic pro-
liferation of CD4+ T cells [39].
Further work is necessary to be able to specify the origin
of regenerated CD8+ cells and either reject or sustain the
explanation of biological distinctions between CD8+ and
CD4+ T cell regenerative pathways. It may be of clinical
importance to determine if a predominance of CD8+ cells
exists of CD8+CD28- and CD8+CD57+ subsets, since a
limited eVectiveness of these populations has been
described in vivo [30]. A signiWcant depression in cell-
mediated immunity in conjunction with possible alterations
of CD8+ T cell subsets in neo patients as compared to con-
trol patients may have implications for the host defence
against foreign pathogens as well as in the immunological
control of disseminated tumour cells.
Although the role of the immune response in controlling
tumour growth and cancer recurrence is controversial, there
is evidence in oesophageal cancer suggesting that T cell
inWltrates have a beneWcial prognostic impact [14]. It was
shown that CD8+ T cell inWltrations within the tumour
specimen have a favourable outcome [35]. And a recent
research in patients with colorectal cancers indicated that
type, density and location of immune cells within tumour
tissues were a better predictor of patient survival than the
current methods to stage colorectal cancers [10, 28]. Inter-
estingly, colorectal tumours from patients without recur-
rence had higher immune cell densities of CD3+ cells
within the tumour and at the inWltrating tumour margin.
Among CD4+ T lymphocytes, Th1 and Th2 phenotypes
can be distinguished [25]. Activation of these two function-
ally distinct subsets of mature T helper cells is of great
importance for an eVective immune response against infec-
tion. Th1 cells are mainly characterised by secretion of IL-2
and IFN- and induce cell-mediated immune responses.
Th2 cells preferentially secrete the cytokines IL-4 and
IL-13 which favour humoural immune responses [7, 33].
Previously published results from our group showed that
oesophagectomy severely depressed host immune responses.
In the present study, neoadjuvant therapy caused both
reduced T cell counts and decreased absolute levels of both
Th1 and Th2 derived cytokines. This is in line with previ-
ous investigations, studying alterations in immune defence
after neoadjuvant treatment [12]. However, in the present
study it was shown that after neoadjuvant therapy produc-
tion of the Th1 and Th2 cytokines per T helper cell was not
decreased and for IL-13 even moderately increased, indi-
cating that reduced cell counts rather than functional deW-
cits contributed to the post-therapy reduction of T cell
cytokine production.
At present, novel therapeutic strategies in oesophageal
cancer mainly focus on applying new chemotherapeutic
drugs, varying drug dosages, optimising the dose of radio-
therapy or on adding hyperthermia to optimise long-term
survival. However, the role of the host immunocompetence
in the inhibition of disease progression and the way it is
altered by the various new therapeutic strategies have only
been partially investigated. The present study shows signiW-
cant disturbances of host cellular immunity induced by pre-
operative thermochemoradiation compared to surgery alone
in oesophageal cancer patients. This neoadjuvant therapy
caused reduced T, NK and B cell counts, reduced overall
Th1 and Th2 cytokine production, and diVerential recovery
of T cytotoxic and T helper cells, leading to prolonged T
cell imbalance that extends beyond the time of surgery.
However, the study group was to small to conclude on the
basis of the immune response whether to stop or continue123
1846 Cancer Immunol Immunother (2008) 57:1837–1847neoadjuvant therapy, although it indicates that for individ-
ual patients it is worthwhile monitoring their immune sta-
tus, having a vigilant attitude toward emerging infections.
The oncological consequences of these immunological
changes need further investigation, as recovery of T helper
cytokine production towards surgery was less impaired
than T helper cell counts.
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